Clinical Trials Browser

Active not recruiting × INDUSTRY × camrelizumab × Clear all

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular